Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors by Rho, Young Hee et al.
ORIGINAL ARTICLE
Drugs Used in the Treatment of Rheumatoid Arthritis:
Relationship between Current Use and Cardiovascular
Risk Factorsadi2_019 34..40
Young Hee Rho, MD, PhD, Annette Oeser, BS, Cecilia P. Chung, MD, MPH, Ginger L. Milne, PhD, and
C. Michael Stein, MD
Divisions of Clinical Pharmacology and Rheumatology, Vanderbilt University School of Medicine, Nashville, TN, USA
DOI: 10.1111/j.1753-5174.2009.00019.x
ABSTRACT
Objectives. Drugs used for the treatment of rheumatoid arthritis (RA) have the potential to affect cardiovascular risk
factors. There is concern that corticosteroids, non-steroidal anti-inﬂammatory drugs (NSAIDs) and COX-2 inhibi-
tors could affect cardiovascular risk adversely, while drugs such as the antimalarial, hydroxychloroquine, may have
beneﬁcial effects. However, there is limited information about cardiovascular risk factors in patients with RA
receiving different drugs.
Methods. We measured cardiovascular risk factors including systolic and diastolic blood pressure, serum HDL and
LDL cholesterol, glucose and homocysteine concentrations and urinary F2-isoprostane excretion in 169 patients
with RA. Risk factors were compared according to current use of corticosteroids, methotrexate, antimalarials,
NSAIDs, COX-2 inhibitors, leﬂunomide and TNF-a blockers. Comparisons were adjusted for age, sex, race, disease
activity (DAS28 score), current hypertension, diabetes, smoking status and statin use.
Results. No cardiovascular risk factor differed signiﬁcantly among current users and non-users of NSAIDs, COX-2
inhibitors, methotrexate and TNF-a blockers. Serum HDL cholesterol concentrations were signiﬁcantly higher in
patients currently receiving corticosteroids (42.2  10.5 vs. 50.2  15.3 mg/dL, adjusted P < 0.001). Diastolic blood
pressure (75.9  11.2 vs. 72.0  9.1 mm Hg, adjusted P = 0.02), serum LDL cholesterol (115.6  34.7 vs.
103.7  27.8 mg/dL, adjusted P = 0.03) and triglyceride concentrations (157.7  202.6 vs. 105.5  50.5 mg/dL,
adjusted P = 0.03) were signiﬁcantly lower in patients taking antimalarial drugs. Plasma glucose was signiﬁcantly
lower in current lefunomide users (93.0  19.2 vs. 83.6  13.4 mg/dL, adjusted P = 0.006).
Conclusions. In a cross-sectional setting drugs used to treat RA did not have major adverse effects on cardiovascular
risk factors and use of antimalarials was associated with beneﬁcial lipid proﬁles.
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Introduction
C
oronary atherosclerosis [1] and cardiovascu-
lar mortality [2] are increased in patients with
rheumatoid arthritis (RA). These patients are
treated with a range of drugs including non-
steroidal anti-inﬂammatory drugs (NSAIDs),
selective cyclo-oxygenase-2 (COX-2) inhibitors,
corticosteroids and disease modifying anti-
rheumatic drugs (DMARDs) including antimala-
rials, methotrexate, tumor necrosis factor alpha
(TNF-a) blockers and leﬂunomide. Drugs used
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For example, in large epidemiological studies
DMARDs such as methotrexate appear to decrease
cardiovascular mortality [3,4], while COX-2 selec-
tive drugs increase it [5,6]. Thus, it is important to
understand the effects of drugs used to treat RA on
cardiovascular risk factors.
There is some information about the effects of
drugs used to treat RA on risk factors. For
example, NSAIDs and COX-2 inhibitors increase
blood pressure [7], high doses of corticosteroids
can cause diabetes [8], and antimalarials may
improve glucose tolerance [9]. However, the infor-
mation available is limited. We examined the
hypothesis that drugs used to treat RA affected
common cardiovascular risk factors.
Methods
Patients and Control Subjects
One hundred and sixty nine (169) patients with RA
were recruited as previously described [1]. Patients
were older than 18 years, fulﬁlled the ACR classi-
ﬁcation criteria for RA, and are participating in
ongoing studies of cardiovascular risk in RA
[10–12]. The study was approved by the Vander-
bilt University Institutional Review Board and
subjects gave written informed consent.
Clinical Measurements and Indices/Scores
Clinical information and laboratory data were
obtained as described [1]. Hypertension was
deﬁned as systolic blood pressure 140 mm Hg,
or diastolic blood pressure 90 mm Hg at enroll-
ment, or currently receiving antihypertensive
treatment. Diabetes was deﬁned as a fasting blood
glucose concentration >126 mg/dL at enrollment
or currently receiving anti-diabetic treatment.
The disease activity score (DAS28) [13] includes 4
measures: a 28 swollen joint count, 28 tender joint
count, the erythrocyte sedimentation rate (ESR),
and patient global estimate of disease status
on a 10 cm visual analog scale (VAS). Patients
were classiﬁed according to whether they were
currently taking or not taking the following
drugs: corticosteroids, methotrexate, antimalari-
als, NSAID, COX-2, leﬂunomide and anti-TNF
blockers. In patients not currently taking these
drugs we recorded whether they were past users.
Fasting plasma glucose and homocysteine and
serum triglyceride, HDL and LDL cholesterol
concentrations were measured at the Vanderbilt
University Medical Center Clinical Laboratory
facilities. Urinary F2-isoprostanes, a measure of
oxidative stress that has been associated with
cardiovascular risk in other studies [14], were
quantiﬁed using gas chromatography and mass
spectroscopy [15] and expressed as ng/mg creati-
nine (ng/mg Cr).
Statistical Analysis
Descriptive statistics were calculated as mean with
standard deviation (SD) according to distributions
of continuous variables. Differences in cardiovas-
cular risk factors such as systolic blood pressure
(SBP), diastolic blood pressure (DBP), concentra-
tions of serum HDL, LDL, and triglycerides,
plasma glucose and homocysteine, and urinary
F2-isoprostane excretion were compared in
patients using or not currently using each drug
using the Wilcoxon rank-sum test. The difference
was further adjusted for age, sex, race, DAS28
score, current hypertension, diabetes, smoking
status and statin use by a multiple linear regression
model. The inclusion of hypertension and diabetes
status as covariates was to account for use of anti-
hypertensive and hypoglycemic agents. Similarly,
adjusting for statin use controlled for differences
in lipids accounted for by therapy. Our goal was to
adjust for confounding as much as possible since
cardiovascular risk is affected by the factors con-
sidered and inﬂammation [11,16]. Thus, while
the results may be conservative they will also
be robust. To exclude the potential confounding
effects of co-therapies we constructed additional
statistical models for each drug that, in addition to
the variables previously included, also adjusted for
the other drugs. Serum triglycerides and urinary
F2-isoprostanes were log-transformed due to their
skewed distribution. Statistical signiﬁcance was
determined using 2-sided 5% signiﬁcance level
(i.e., P value <0.05). Statistical analysis was per-
formed using R 2.7.2 (http://www.r-project.org).
Results
The characteristics of the patients are shown in
Table 1. The patients were predominantly middle-
aged and female, reﬂecting the epidemiology of
RA. The differences in cardiovascular risk factors
between current users and non-user of each par-
ticular class of drug are shown in Tables 2 to 8. No
cardiovascular risk factor differed signiﬁcantly
among current users and non-users of NSAIDs,
COX-2 inhibitors, methotrexate and TNF-a
blockers.
Drugs, Cardiovascular Risk Factors and RA 35
Arch Drug Info 2009;2:34–40Current corticosteroid use was associated
with higher HDL cholesterol concentrations
(42.2  10.5 vs. 50.2  15.3 mg/dL, adjusted
P < 0.001). Current use of antimalarial therapy
(almost exclusively hydroxychloroquine) was
associated with lower diastolic blood pressure
(75.9  11.2 vs. 72.0  9.1 mm Hg, adjusted
P = 0.02), serum LDL (115.6  34.7 vs.
103.7  27.8 mg/dL, adjusted P = 0.03) and
triglyceride concentrations (157.7  202.6 vs.
105.5  50.5 mg/dL, adjusted P = 0.03). Plasma
glucose was signiﬁcantly lower in patients taking
lefunomide (93.0  19.2 vs. 83.6  13.4 mg/dL,
adjusted P = 0.006). In a post-hoc analysis,
current leﬂunomide use was associated with a
marginally lower body mass index (BMI)
(29.5  6.8 vs. 27.5  6.3 kg/m
2, Wilcoxon
rank-sum P = 0.08, adjusted P = 0.07). Statisti-
cal models that additionally adjusted for the
other drugs under consideration yielded very
similar results: there was no change in statis-
tical signiﬁcance for any comparison except that
HDL cholesterol concentrations were signiﬁ-
cantly higher in patients taking antimalarials
(P = 0.03).
Table 1 Descriptive statistics of the study group (N = 169)
Factor
Mean  SD or
percentage
Sex (males) 30.8%
Age (years) 54.2  11.8
Race (Caucasians) 88.2%
DAS28 score 3.79  1.61
Hypertension 53.3%
Diabetes 11.2%
Statin use 12.4%
Systolic blood pressure (mm Hg) 133.3  20.3
Diastolic blood pressure (mm Hg) 74.9  10.8
HDL (mg/dL) 46.6  13.9
LDL (mg/dL) 112.7  33.4
Triglycerides (mg/dL) 144.6  178.5
Glucose (mg/dL) 91.2  18.6
Homocysteine (mmol/L) 10.5  3.4
F2-Isoprostanes (ng/mg Creatinine) 3.49  3.80
Current corticosteroid use 54.4%
Current methotrexate use 71.0%
Current antimalarial use 24.9%
Current NSAID use 33.1%
Current COX-2 inhibitor use 30.2%
Current leﬂunomide use 18.3%
Current anti-TNF blocker use 20.7%
Past steroid use 34.3%
Past methotrexate use 20.1%
Past antimalarial use 13.0%
Past NSAID use 18.9%
Past COX-2 inhibitor use 36.7%
Past anti-TNF blocker use 6.5%
Table 2 Cardiovascular risk factors and current corticosteroid use
Risk factor
No steroids
(N = 77)
Current steroid
use (N = 92) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 134.1  20.2 132.7  20.5 0.51 1.47 (-3.35–6.29) 0.55
Diastolic BP (mm Hg) 73.2  10.3 76.4  11.1 0.06 2.71 (-0.39–5.82) 0.09
HDL (mg/dL) 42.2  10.5 50.2  15.3 <0.001 9.47 (5.66–13.27) <0.001
LDL (mg/dL) 115.4  33.0 110.4  33.8 0.44 -5.19 (-15.9–5.53) 0.34
Triglycerides (mg/dL) 146.8  97.2 142.8  225.2 0.004 -0.11 (-0.27–0.06) 0.22
Glucose (mg/dL) 93.8  19.5 89.1  17.5 0.01 -3.86 (-8.45–0.74) 0.10
Homocysteine (mmol/L) 9.90  2.80 11.02  3.70 0.07 0.64 (-0.3–1.58) 0.18
F2-Isoprostanes (ng/mg Cr) 3.30  2.53 3.66  4.61 0.75 0.08 (-0.12–0.28) 0.44
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
Table 3 Cardiovascular risk factors and current methotrexate use
Risk factor
No methotrexate
(N = 49)
Current methotrexate
use (N = 120) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 137.5  18.0 131.6  21.0 0.09 -1.35 (-6.67–3.97) 0.62
Diastolic BP (mm Hg) 77.9  9.5 73.7  11.1 0.02 -1.85 (-5.29–1.59) 0.29
HDL (mg/dL) 43.5  11.0 47.8  14.8 0.12 2.89 (-1.62–7.39) 0.21
LDL (mg/dL) 115.0  38.1 111.7  31.4 0.75 -4.15 (-16.04–7.74) 0.50
Triglycerides (mg/dL) 150.0  113.0 142.0  200.0 0.18 -0.11 (-0.3–0.07) 0.24
Glucose (mg/dL) 92.2  21.5 90.9  17.3 0.91 2.91 (-2.19–8.01) 0.27
Homocysteine (mmol/L) 11.49  4.28 10.11  2.82 0.10 -0.47 (-1.51–0.58) 0.38
F2-Isoprostanes (ng/mg Cr) 3.31  2.31 3.57  4.27 0.96 -0.10 (-0.32–0.12) 0.36
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients mean reﬂect differences in log-units than raw units.
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Risk factor
No antimalarials
(N = 127)
Current antimalarial
use (N = 42) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 135.5  19.8 126.7  20.5 0.01 -4.59 (-9.99–0.82) 0.10
Diastolic BP (mm Hg) 75.9  11.2 72.0  9.1 0.047 -4.04 (-7.52 – -0.56) 0.02
HDL (mg/dL) 45.3  13.7 50.4  14.1 0.03 3.94 (-0.62–8.5) 0.09
LDL (mg/dL) 115.6  34.7 103.7  27.8 0.07 -13.37 (-25.29 – -1.45) 0.03
Triglycerides (mg/dL) 157.7  202.6 105.5  50.5 0.006 -0.21 (-0.4 – -0.02) 0.03
Glucose (mg/dL) 92.2  18.8 88.4  17.7 0.09 -0.01 (-5.26–5.23) 1.00
Homocysteine (mmol/L) 10.56  3.21 10.34  3.78 0.59 0.10 (-0.97–1.16) 0.86
F2-Isoprostanes (ng/mg Cr) 3.60  4.23 3.18  2.00 0.87 -0.11 (-0.33–0.12) 0.35
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
Table 5 Cardiovascular risk factors and current NSAID use
Risk factor
No NSAIDs
(N = 113)
Current NSAID
use (N = 56) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 134.5  20.8 130.8  19.3 0.34 -1.03 (-6.12–4.07) 0.69
Diastolic BP (mm Hg) 75.5  10.7 73.8  10.9 0.27 -0.65 (-3.96–2.66) 0.70
HDL (mg/dL) 46.8  13.4 46.1  15.0 0.66 2.33 (-1.96–6.63) 0.29
LDL (mg/dL) 113.7  34.0 110.5  32.3 0.62 -0.85 (-12.2–10.49) 0.88
Triglycerides (mg/dL) 148.7  208.7 136.4  90.4 0.79 -0.03 (-0.21–0.14) 0.71
Glucose (mg/dL) 90.6  16.2 92.6  22.7 0.71 -0.39 (-5.29–4.52) 0.88
Homocysteine (mmol/L) 10.61  3.30 10.29  3.48 0.59 -0.05 (-1.05–0.95) 0.92
F2-Isoprostanes (ng/mg Cr) 3.19  2.40 4.11  5.62 0.17 0.11 (-0.1–0.32) 0.31
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
Table 6 Cardiovascular risk factors and current COX-2 inhibitor use
Risk factor
No COX-2
inhibitors
(N = 118)
Current COX-2
inhibitor use
(N = 51) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 133.7  20.5 132.5  19.9 0.60 -1.66 (-6.75–3.44) 0.53
Diastolic BP (mm Hg) 75.2  10.9 74.3  10.6 0.58 -0.9 (-4.21–2.42) 0.60
HDL (mg/dL) 46.1  13.0 47.7  15.8 0.78 0.13 (-4.18–4.44) 0.95
LDL (mg/dL) 114.4  34.3 108.8  31.2 0.33 -8.24 (-19.5–3.03) 0.15
Triglycerides (mg/dL) 151.6  208.1 128.7  75.0 0.93 -0.03 (-0.2–0.15) 0.76
Glucose (mg/dL) 91.9  20.5 89.8  13.0 0.82 0.32 (-4.59–5.22) 0.90
Homocysteine (mmol/L) 10.69  3.50 10.09  2.97 0.32 -0.32 (-1.32–0.67) 0.53
F2-Isoprostanes (ng/mg Cr) 3.59  4.17 3.28  2.78 0.44 -0.04 (-0.25–0.17) 0.69
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
Table 7 Cardiovascular risk factors and current leﬂunomide use
Risk factor
No leﬂunomide
(N = 138)
Current leﬂunomide
use (N = 31) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 132.6  20.3 136.6  20.2 0.28 5.7 (-0.32–11.73) 0.07
Diastolic BP (mm Hg) 74.6  10.6 76.5  11.6 0.33 1.41 (-2.54–5.35) 0.49
HDL (mg/dL) 46.4  14.1 47.1  13.4 0.69 0.74 (-4.39–5.88) 0.78
LDL (mg/dL) 111.5  33.3 117.9  34.2 0.28 8.40 (-5.06–21.86) 0.22
Triglycerides (mg/dL) 145.0  187.8 143.0  132.2 0.59 0.02 (-0.19–0.23) 0.86
Glucose (mg/dL) 93.0  19.2 83.6  13.4 0.01 -8.12 (-13.84 – -2.41) 0.006
Homocysteine (mmol/L) 10.37  3.20 11.09  3.97 0.68 0.50 (-0.69–1.68) 0.41
F2-Isoprostanes (ng/mg Cr) 3.36  4.02 4.07  2.59 0.03 0.19 (-0.06–0.44) 0.15
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
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The major ﬁndings of this study are that in a
cross-sectional setting drugs used to treat RA did
not have major adverse effects on cardiovascular
risk factors and antimalarial use was associated
with beneﬁcial lipid proﬁles.
Corticosteroids
Corticosteroids are thought to induce dyslipi-
demia through impaired catabolism of LDL, and
increased lipoprotein lipase activity [17]. They can
also induce hypertension and glucose intolerance
[8,17]. Although we found that corticosteroid use
was associated with increased HDL concentra-
tions, this requires cautious interpretation in terms
of implications for cardiovascular risk, since a drug
that raised HDL cholesterol was associated with
increased mortality in randomized trials [18,19]
and the functional capacity of HDL may be more
important than its concentrations. Our ﬁndings in
RA differ from those in SLE where corticosteroid
use was associated with increased triglycerides
[20]. The reason for this difference is not clear, but
may be related to the more frequent use of high
doses of corticosteroids in SLE.
Methotrexate
The reported association between methotrexate
use and increased concentrations of homocysteine,
a cardiovascular risk factor, is a concern [21]. We
found that homocysteine concentrations did not
differ in patients receiving or not receiving meth-
otrexate; this may have been the result of concur-
rent folate administration [22], which is common
practice and routine in our cohort.
Antimalarials
Antimalarials may have potential beneﬁts on car-
diovascular risk since they are associated with
lower LDL cholesterol and triglycerides, concor-
dant with other studies [9,23]. They were also
associated with lower blood pressure. While the
hypotensive effects of antimalarials are well
known [24,25], these ﬁndings were mainly with
chloroquine used to treat malaria and not
with hydroxychloroquine in a rheumatological
setting. Thus, our ﬁndings suggesting that
hydroxychloroquine is associated with lower
blood pressure in a rheumatological setting, is a
novel ﬁnding. The effects of antimalarials in this
cohort of patients with RA are much more
prominent than in our previous report in patients
with SLE in whom use of antimalarials was not
associated with differences in cardiovascular risk
factors [20].
NSAIDs and COX-2 Inhibitors
The lack of a signiﬁcant association between the
use of NSAIDs and COX-2 inhibitors and cardio-
vascular risk factors in this RA cohort replicates
ﬁndings in SLE [20] but needs cautious interpre-
tation; the adverse effects of NSAIDs and COX-2
inhibitors, particularly on blood pressure, are well
documented [5–7]. There could be a bias by indi-
cation to select low-risk patients for such thera-
pies. Also, patients who had previously become
hypertensive on NSAID therapy may have had
these medications discontinued.
Leﬂunomide andTNF-a Blockers
Associations between leﬂunomide and cardiovas-
cular risk factors are not well described although
there are some reports of leﬂunomide increasing
blood pressure [26]. The ﬁnding of lower plasma
glucose concentrations with leﬂunomide use is
novel and may derive in part from a decrease in
body weight, a known side-effect of leﬂunomide
[27]. TNF-a blockers, may improve insulin sensi-
Table 8 Cardiovascular risk factors and current TNF-a blocker use
Risk factor
No TNF blockers
(N = 134)
Current TNF
blocker use
(N = 35) P value Beta* (95%CI) P value*
Systolic BP (mm Hg) 133.6  21.2 132.2  16.7 0.91 1.73 (-4.08–7.53) 0.56
Diastolic BP (mm Hg) 74.6  10.7 76.3  11.1 0.36 3.47 (-0.26–7.21) 0.07
HDL (mg/dL) 45.6  13.7 50.2  14.2 0.06 2.87 (-2.01–7.75) 0.25
LDL (mg/dL) 111.6  31.1 116.7  41.2 0.92 3.71 (-9.18–16.6) 0.57
Triglycerides (mg/dL) 136.4  96.4 176.1  345.2 0.97 0.03 (-0.17–0.23) 0.76
Glucose (mg/dL) 92.7  19.2 85.7  14.7 0.04 -3.48 (-9.04–2.09) 0.22
Homocysteine (mmol/L) 10.82  3.46 9.29  2.60 0.008 -0.86 (-1.99–0.28) 0.14
F2-Isoprostanes (ng/mg Cr) 3.26  2.44 4.42  6.92 0.25 0.18 (-0.07–0.42) 0.15
*Adjusted for age, sex, race, DAS28, hypertension status, diabetes status, current statin use and current smoking status.
Beta indicates the raw regression coefficient of each drug in the adjusted model.
Note that triglycerides and F2-isoprostanes were log-transformed so the coefficients reﬂect mean differences in log-units than raw units.
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study no effects on glucose or lipid concentrations
were observed.
Limitations of the Study
This study has several limitations. First, it was
cross-sectional, and the pattern of drug use may
have been affected by indication bias. Also current
drug use does not always reﬂect the true effects of
the drug since the duration of drug use needs to be
considered, which was not available; we did not
analyze information about past use of a drug in
patients not currently taking a particular drug.
Also, we did not study additional cardiovascular
risk markers such as EKG ﬁndings or elevated
BNP levels.
Second, since the study was exploratory, we per-
formed multiple statistical comparisons without
statistical adjustment and the ﬁndings should be
interpreted in that light. Nevertheless, since ran-
domized controlled trials to examine the effects of
the drugs of interest on cardiovascular risk factors
in RA are not feasible, the study provides useful
information, despite its limitations.
Corresponding Author: Young Hee Rho, MD, PhD,
Division of Clinical Pharmacology, Vanderbilt Uni-
versity, T-3207 MCN, Nashville, TN 37232, USA.
Tel: (615) 322-4665; Fax: (615) 936-2746; E-mail:
david.y.rho@vanderbilt.edu
Conﬂict of Interest: None of the authors has a conﬂict of
interest related to this work.
References
1 Chung CP, Oeser A, Raggi P, Gebretsadik T,
Shintani AK, Sokka T, et al. Increased coronary-
artery atherosclerosis in rheumatoid arthritis: Rela-
tionship to disease duration and cardiovascular risk
factors. Arthritis Rheum 2005;52:3045–53.
2 Pincus T, Callahan LF. Taking mortality in rheu-
matoid arthritis seriously—Predictive markers,
socioeconomic status and comorbidity. J Rheumatol
1986;13:841–5.
3 Choi HK, Hernan MA, Seeger JD, Robins JM,
Wolfe F. Methotrexate and mortality in patients
with rheumatoid arthritis: A prospective study.
Lancet 2002;359:1173–7.
4 Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J,
Horslev-Petersen K, Luukkainen RK, et al. Cardio-
vascular disease in patients with rheumatoid arthri-
tis: Results from the QUEST-RA study. Arthritis
Res Ther 2008;10:R30.
5 Bresalier RS, Sandler RS, Quan H, Bolognese JA,
Oxenius B, Horgan K, et al. Cardiovascular events
associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N Engl J Med 2005;352:
1092–102.
6 Bertagnolli MM, Eagle CJ, Zauber AG, Redston M,
Solomon SD, Kim K, et al. Celecoxib for the pre-
vention of sporadic colorectal adenomas. N Engl J
Med 2006;355:873–84.
7 Brooks PM. Non-steroidal anti-inﬂammatory
drugs. In: Hochberg MC, Silman AJ, Smolen JS,
Weinblatt ME, Weisman MH, eds. Rheumatology,
3rd edition. London: Elsevier; 2003:377–84.
8 Buchman AL. Side effects of corticosteroid therapy.
J Clin Gastroenterol 2001;33:289–94.
9 Petri M. Hydroxychloroquine use in the Baltimore
lupus cohort: Effects on lipids, glucose and throm-
bosis. Lupus 1996;5(suppl 1):S16–22.
10 Chung CP, Oeser A, Avalos I, Gebretsadik T,
Shintani A, Raggi P, et al. Utility of the Framing-
ham risk score to predict the presence of coronary
atherosclerosis in patients with rheumatoid arthritis.
Arthritis Res Ther 2006;8:R186.
11 Chung CP, Oeser A, Solus JF, Gebretsadik T,
Shintani A, Avalos I, et al. Inﬂammation-associated
insulin resistance: Differential effects in rheumatoid
arthritis and systemic lupus erythematosus deﬁne
potential mechanisms. Arthritis Rheum 2008;58:
2105–12.
12 Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik
T, Shintani A, et al. Amino-terminal fragment of
the prohormone brain-type natriuretic peptide in
rheumatoid arthritis. Arthritis Rheum 2008;58:
2662–9.
13 Prevoo ML, van ‘t Hof MA, Kuper HH,
van Leeuwen MA, van de Putte LB, van Riel PL.
Modiﬁed disease activity scores that include twenty-
eight-joint counts. Development and validation
in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum 1995;38:
44–8.
14 Montuschi P, Barnes P, Roberts LJ. Insights into
oxidative stress: The isoprostanes. Curr Med Chem
2007;14:703–17.
15 Milne GL, Sanchez SC, Musiek ES, Morrow
JD. Quantiﬁcation of F2-isoprostanes as a bio-
marker of oxidative stress. Nat Protoc 2007;2:
221–6.
16 Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik
T, Shintani A, et al. Prevalence of the metabolic
syndrome is increased in rheumatoid arthritis and is
associated with coronary atherosclerosis. Athero-
sclerosis 2007.
17 Sholter DE, Armstrong PW. Adverse effects of cor-
ticosteroids on the cardiovascular system. Can J
Cardiol 2000;16:505–11.
18 Barter PJ, Caulﬁeld M, Eriksson M, Grundy SM,
Kastelein JJ, Komajda M, et al. Effects of torce-
trapib in patients at high risk for coronary events. N
Engl J Med 2007;357:2109–22.
Drugs, Cardiovascular Risk Factors and RA 39
Arch Drug Info 2009;2:34–4019 Pearson H. When good cholesterol turns bad.
Nature 2006;444:794–5.
20 Rho YH, Oeser A, Chung CP, Morrow JD,
Stein CM. Drugs to treat systemic Lupus Erythe-
matosus: Relationship between current use and
cardiovascular risk factors. Arch Drug Inf 2008;1:
23–8.
21 Desouza C, Keebler M, McNamara DB, Fonseca V.
Drugs affecting homocysteine metabolism: Impact
on cardiovascular risk. Drugs 2002;62:605–16.
22 Whittle SL, Hughes RA. Folate supplementation
and methotrexate treatment in rheumatoid arthritis:
A review. Rheumatology (Oxford) 2004;43:267–71.
23 Petri M, Lakatta C, Magder L, Goldman D. Effect
of prednisone and hydroxychloroquine on coronary
artery disease risk factors in systemic lupus erythe-
matosus: A longitudinal data analysis. Am J Med
1994;96:254–9.
24 Anigbogu CN, Adigun SA, Inyang I, Adegunloye
BJ. Chloroquine reduces blood pressure and
forearm vascular resistance and increases forearm
blood ﬂow in healthy young adults. Clin Physiol
1993;13:209–16.
25 Musabayane CT, Musvibe A, Wenyika J, Munjeri
O, Osim EE. Chloroquine inﬂuences renal function
in rural Zimbabweans with acute transient fever.
Ren Fail 1999;21:189–97.
26 Rozman B, Praprotnik S, Logar D, Tomsic M,
Hojnik M, Kos-Golja M, et al. Leﬂunomide and
hypertension. Ann Rheum Dis 2002;61:567–9.
27 Coblyn JS, Shadick N, Helfgott S. Leﬂunomide-
associated weight loss in rheumatoid arthritis.
Arthritis Rheum 2001;44:1048–51.
28 Huvers FC, Popa C, Netea MG, van den Hoogen
FH, Tack CJ. Improved insulin sensitivity by anti-
TNFalpha antibody treatment in patients with
rheumatic diseases. Ann Rheum Dis 2007;66:
558–9.
29 Popa C, van den Hoogen FH, Radstake TR, Netea
MG, Eijsbouts AE, den Heijer M, et al. Modulation
of lipoprotein plasma concentrations during long-
term anti-TNF therapy in patients with active
rheumatoid arthritis. Ann Rheum Dis 2007;66:
1503–7.
40 Rho et al.
Arch Drug Info 2009;2:34–40